TayaCho/E+ via Getty Images Late last week, Wells Fargo put out a large list of potential and logical buyout targets in the biotech sector. They focused on the midcap space for various reasons. One of the names on the report was Viking Therapeutics, Inc. (VKTX), which is on my short list of likely biotech acquisitions as well. However, I recently covered this mid-cap GLP-1 concern in this article, and I haven't been alone (I, II) here on Seeking Alpha in reaching that conclusion. Today, we highlight three o ...